Every clinician knows that within any diagnosis, including the psychoses, individual patients appear quite different. While research rating scales can capture these variations, clinicians who treat psychotic disorders have not adopted these scales in the way that those who treat depression made the Hamilton and Beck scales commonplace tools. Eight dimensions can now be rated, either by clinicians or clinical researchers, from absent to severe on a simple 0–4 scale: delusions, hallucinations, disorganized thinking, negative symptoms, psychomotor symptoms, cognition, depression, and mania. The Psychosis Work Group believes that these domains of pathology, now in Section 3 of DSM-5 (“Conditions for Further Study”), are essential to evaluate patients, address treatment, and relate psychopathology to identified behavioral constructs. In the future, these domains may provide a bridge to National Institute of Mental Health research in the Research Domain Criteria framework. We believe that new therapies targeting one or more of these domains specifically, in the context of the life course of a patient’s illness, will someday by approved by the Food and Drug Administration and other regulatory bodies.